NCO-650 free base is an antiallergic agent that acts by inhibiting tryptase, a key trypsin-like protease in mast cells. NCO-650 free base inhibits mast cell histamine release, increases intracellular cAMP levels in mast cells, suppresses bronchoconstriction, and prevents decreases in perfusion pressure and systemic blood pressure. NCO-650 free base is applicable to the research of allergic diseases and bronchial asthma.

N-Cholyl-L-leucine is a bile acid-amino acid conjugate, mainly produced by intestinal microorganisms. N-Cholyl-L-leucine can be used as a biomarker for premature infants and is also employed in the study of bile acid metabolism.

N-Chloroacetyl-L-tryptophan (Chloroacetyltryptophan) is a hydrolyzable tryptophan derivative. N-Chloroacetyl-L-tryptophan rapidly hydrolyzes to tryptophan in Pseudomonas aurantiaca cultures. N-Chloroacetyl-L-tryptophan increases the level of the antibiotic Pyrrolnitrin in Pseudomonas aurantiaca fermentation cultures.

NBI 30545 is a blood-brain barrier permeable CRF1R antagonist with a Ki value of 3.4 nM for the human receptor. NBI 30545 inhibits CRF-stimulated intracellular cAMP accumulation and ACTH release. NBI 30545 can be used in the research of depression, anxiety disorders and stress-related diseases.

N-Benzylsulfamide is a benzyl-substituted sulfamide reagent. N-Benzylsulfamide can be used as a synthetic precursor to generate dioxides of bicyclic thiadiazines.

NBD Sphingosine-1-phosphate (ammonium) is a sphosphingolipid.

NB-7 (example 12) is a potent and orally active SARM1 inhibitor with an IC50 < 1 μM. NB-7 can be used for neurological disorders research.

NB-216 is an orally active and brain-penetrant BACE-1 inhibitor (IC50 = 17 nM). NB-216 has a strong inhibitory effect on cathepsin D (IC50 = 1 nM) and cathepsin E (IC50 = 0.4 nM). NB-216 can be used for the study of Alzheimer's disease.

Nav1.8-IN-22 (Formula I) is a Nav1.8 sodium channel inhibitor. Nav1.8-IN-22 regulates sodium channel activity by directly binding to Nav1.8. Nav1.8-IN-22 is applicable for pain-related research.

Nav1.8-IN-21 is a potent and selective Nav1.8 inhibitor with analgesic activity. Nav1.8-IN-21 can be used for analgesia Research.

Naproxen methyl ester is a prodrug of Naproxen and an ester derivative. Naproxen methyl ester is promising for research of arthritis and other inflammatory conditions1.

Nandinine is an orally active derivative of Berberine. Nandinine enhances AMPK activity, inhibits the activation of IKKβ/NF-κB, and regulates the phosphorylation of IRS-1. Nandinine reverses the abnormal production of adipokines, promotes insulin-mediated glucose uptake, and alleviates insulin resistance. Nandinine improves glucose tolerance and increases the insulin sensitivity index in mice. Nandinine can be used in studies related to insulin resistance.

Nampt-IN-18 (Compound Q24) is an orally active NAMPT inhibitor with an IC50 of 8.0 nM against hNAMPT. Nampt-IN-18 inhibits NAMPT enzymatic activity. Nampt-IN-18 inhibits DNA synthesis and induces Apoptosis. Nampt-IN-18 exhibits anticancer activity against gastric cancer and colorectal cancer. Nampt-IN-18 can be used for the research of gastrointestinal cancers.

Nampt-IN-17 is an selective orally active NAMPT inhibitor with a human NAMPT IC50 of 17 nM and Ki of 25.9 nM. Nampt-IN-17 depletes intracellular NAD+ and ATP, disrupts mitochondrial membrane potential, suppresses cell proliferation, self-renewal, invasion, and migration, induces cell-cycle arrest and apoptosis. Nampt-IN-17 exhibits selective activity against NAPRT-deficient gastric cancer cells. Nampt-IN-17 can be used for the research of NAPRT-deficient gastric cancer.

NAMPT activator-9 (Compound DIPM) is an allosteric, non-competitive NAMPT activator, with an EC50 of 3.366 μM against hNAMPT. NAMPT activator-9 enhances the enzymatic activity of NAMPT via an allosteric, non-competitive mechanism. NAMPT activator-9 increases intracellular NAD+ levels. NAMPT activator-9 restores myotube diameter and reduces the expression of atrophy markers Atrogin-1 and MuRF1. NAMPT activator-9 is applicable to research related to muscle atrophy.

Nafagrel hydrochloride is a thromboxane A2 synthetase inhibitor. Nafagrel hydrochloride can prevent the accumulation of thrombus material in a rat model of acute arterial thrombosis.

nAChR antagonist 3 is a selective α7 nAChR antagonist with an IC50 of 0.86 μM. nAChR antagonist 3 exerts a protective effect against paraoxon-induced toxicity. nAChR antagonist 3 can be used for the research of organophosphate poisoning.

NA0359 is a derivative of SF2370. NA0359 inhibits the actin-myosin-ATP interaction in native smooth muscle actomyosin and myosin light chain phosphorylation.

N4-Acetyldeoxycytidine triphosphate is a terminal deoxynucleotidyl transferase substrate. N4-Acetyldeoxycytidine triphosphate acts as a substrate for calf thymus terminal deoxynucleotidyl transferase and undergoes polymerization to form extended polydeoxynucleotide chains.

N3C14SOBRAC is a SOBRAC with an azide group at the end can be used in click chemical reactions. SOBRAC is an inhibitor of acidic ceramidase.

N2-Succinyl-L-ornithine is a nucleoside metabolite.

N1-Phenylsuberamide is an organic amide compound, and its structure can be regarded as a simplified analogue of Vorinostat. N1-Phenylsuberamide exhibits moderate anti-proliferative activity against MDA-MB-231 and MCF-7 cells. N1-Phenylsuberamide does not show significant HDAC inhibitory activity and can only weakly induce the expression of the p21 gene. N1-Phenylsuberamide has extremely low relative binding affinity of estrogen receptor. N1-Phenylsuberamide can be used as a control compound.

N,N-Dimethyl psychosine is a derivative of Psychosine. N,N-Dimethyl psychosine can be used as an internal standard compound to quantify Psychosine in alkaline-treated lipid extracts.

N-(Phenylacetyl)-L-phenylalanine is an amino acid analog. N-(Phenylacetyl)-L-phenylalanine is produced via the enantioselective acylation of L-phenylalanine catalyzed by penicillin G acylase from Alcaligenes faecalis. N-(Phenylacetyl)-L-phenylalanine undergoes hydrolysis in aqueous media.

Myristoleyl methane sulfonate is a lipid.

Myosin-IN-4 (Compound 3), a pyridine-2,4-dione derivative, is a myocardial myosin inhibitor. Myosin-IN-4 has a strong inhibitory activity against cardiac myosin ATPase with an IC50 value of 0.73 μM. Myosin-IN-4 exert a negative inotropic effect by inhibiting myocardial contraction. Myosin-IN-4 can be used for the research on cardiovascular diseases related to cardiac myosin.

Myosin-IN-3 (Compound 4-1) is a pyrimidine ketone derivative. Myosin-IN-3 exhibits significant anti ferroptotic activity (IC50 = 3.11 μM) while possessing myosin (IC50 = 3.09 μM) inhibitory activity and antioxidant activity (DPPH EC50 = 23.17 μM; MDA EC50 = 55.34 μM). Myosin-IN-3 can be used for research on heart conditions such as hypertrophic cardiomyopathy.

Mutant p53 modulator-2 (Compound 1988) is a mutant p53 modulator. Mutant p53 modulator-2 can be used in the research of cancer.

Multitarget AD-IN-7 is an orally active multi-target anti-AD compound. Multitarget AD-IN-7 exhibits inhibitory activity against GSK-3β and GSK-3α (IC50 = 0.66, 0.83 nM). Multitarget AD-IN-7 upregulates the expression of p-GSK-3β-Ser9, inhibits the phosphorylation of tau-Ser396, targets Aβ1-42, chelates pathogenic metal ions, scavenges ABTS•+, upregulates the expression of β-catenin and neurogenesis biomarkers, and promotes neurite outgrowth. Multitarget AD-IN-7 improves motor ability in Alzheimer's disease zebrafish. Multitarget AD-IN-7 is applicable to research related to Alzheimer's disease.

Multi-kinase-IN-11 (Compound 1a) is a DFG-out conformation-targeted multi-kinase inhibitor, including SRC, LCK, ABL, PYK2, CSK, HCK, P38 and C-KIT. Multi-kinase-IN-11 serves as a scaffold for the preparation of fluorescently labeled binding probes and affinity matrices.